Clinical trial
GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic…
NCT00110721 · Galectin Therapeutics Inc., Industry · Terminated
Key facts
| NCT number | NCT00110721 |
|---|---|
| Title | GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer |
| Official title | A Phase II, Multi-Center, Open-Label Trial to Evaluate the Efficacy and Safety of Intravenous GM-CT-01 in Combination With 5-Fluorouracil When Administered in Monthly Cycles as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer |
| Lead sponsor | Galectin Therapeutics Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | GM-CT-01 plus 5-Fluorouracil |
| Enrollment | 20 |
| Start date | May 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | May 13, 2005 |
| Last update posted | Mar 6, 2012 |
| Countries | Israel, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: